Emerald Mutual Fund Advisers Trust Fibrogen Inc Transaction History

Emerald Mutual Fund Advisers Trust

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2018 Oct 31, 2018	SELL	$56.3 - $67.25 $3.42 Million - $4.08 Million	-60,660 Reduced 18.98%	258,863 $15.7 Million
Q2 2018 Jul 31, 2018	BUY	$44.9 - $64.95 $14.3 Million - $20.8 Million	319,523 New	319,523 $20 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Emerald Mutual Fund Advisers Trust, based on Form 13F filings with the SEC.

Stay updated on Emerald Mutual Fund Advisers Trust with notifications on news.